Duotril 400 EC Emulsionskoncentrat Dinamarca - danès - SEGES Landbrug & Fødevarer

duotril 400 ec emulsionskoncentrat

adama northern europe b.v. - ioxynil, bromoxynil - emulsionskoncentrat - 160 g/l ioxynil ; 240 g/l bromoxynil

Agros Bromox Emulsionskoncentrat Dinamarca - danès - SEGES Landbrug & Fødevarer

agros bromox emulsionskoncentrat

agros - ioxynil, bromoxynil - emulsionskoncentrat - 160 g/l ioxynil ; 240 g/l bromoxynil

LFS Bromoxynil+Ioxynil Flydende middel Dinamarca - danès - SEGES Landbrug & Fødevarer

lfs bromoxynil+ioxynil flydende middel

lfs kemi - ioxynil, bromoxynil - flydende middel - 200 g/l ioxynil ; 200 g/l bromoxynil

Briotril Flydende middel Dinamarca - danès - SEGES Landbrug & Fødevarer

briotril flydende middel

bayer a/s - ioxynil, bromoxynil - flydende middel - 160 g/l ioxynil ; 240 g/l bromoxynil

Bromyl Flydende middel Dinamarca - danès - SEGES Landbrug & Fødevarer

bromyl flydende middel

inter-trade a/s - ioxynil, bromoxynil - flydende middel - 200 g/l ioxynil ; 200 g/l bromoxynil

Oxinol Flydende middel Dinamarca - danès - SEGES Landbrug & Fødevarer

oxinol flydende middel

kvk agro a/s - ioxynil, bromoxynil, clopyralid, mechlorprop - flydende middel - 50 g/l ioxynil ; 50 g/l bromoxynil ; 15 g/l clopyralid ; 333 g/l mechlorprop

Cosentyx Unió Europea - danès - EMA (European Medicines Agency)

cosentyx

novartis europharm limited - secukinumab - arthritis, psoriatic; psoriasis; spondylitis, ankylosing - immunosuppressiva - plaque psoriasiscosentyx is indicated for the treatment of moderate to severe plaque psoriasis in adults and children from the age of 6 years old who are candidates for systemic therapy. hidradenitis suppurativa (hs)cosentyx is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults with an inadequate response to conventional systemic hs therapy. psoriasis arthritiscosentyx, alene eller i kombination med methotrexat (mtx), er indiceret til behandling af aktiv psoriasis artrit hos voksne patienter, når svar på tidligere sygdomsmodificerende anti-reumatiske lægemidler (dmard) behandling har været mangelfuld. aksial spondyloarthritis (axspa)ankyloserende spondylitis (som, røntgen aksial spondyloarthritis)cosentyx er indiceret til behandling af aktiv ankyloserende spondylitis i voksne, der har reageret tilstrækkeligt til konventionel behandling. non-radiographic axial spondyloarthritis (nr-axspa)cosentyx is indicated for the treatment of active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) evidence in adults who have responded inadequately to non steroidal anti inflammatory drugs (nsaids). juvenile idiopathic arthritis (jia)enthesitis-related arthritis (era)cosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active enthesitis-related arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy. juvenile psoriatic arthritis (jpsa)cosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active juvenile psoriatic arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.